Role of interleukin 33 in human immunopathology

Annals of the Rheumatic Diseases

Volumn 69, Issue SUPPL. 1, 2010, Pages

  Murphy, G E J ^a   Xu, D ^a   Liew, F Y ^a   McInnes, I B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; PROTEIN ST2L; UNCLASSIFIED DRUG; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; DRUG MECHANISM; HEART FAILURE; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; AUTOIMMUNE DISEASE; CELL COMMUNICATION; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 75749087164     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.120113     Document Type: Review

References (72)

1. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005;17:289-92.
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
3. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90.
4. Moritz DR, Rodewald HR, Gheyselinck J, et al. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998;161:4866-74.
5. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930-5.
6. Leung BP, Xu D, Culshaw S, et al. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173:145-50.
7. Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999;19:1279-88.
8. Baekkevold ES, Roussigne M, Yamanaka T, et al. Molecular characterization of NFHEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003;163:69-79.
9. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Bioophys Res Commun 2009;384:105-9.
10. Palmer G, Talabot-Ayer D, Viatte S, et al. The new interleukin (IL)-1 family cytokine IL-33 is expressed by human synovial fibroblasts and its production is increased by IL-1 beta and TNF alpha. Ann Rheum Dis 2008;67:A27-8.
11. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007;104:282-7.
12. Kuchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008;173:1229-42.
13. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009;106:9021-6.
14. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008;3:e3331.
15. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49.
16. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008;105:10913-8.
17. Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009;60:738-49.
18. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 2000;11:483-6.
19. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
20. Li H, Willingham SB, Ting JPY, et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181:17-21.
21. Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009;284:19420-6.
22. Hudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008;84:631-3.
23. Haraldsen G, Balogh J, Pollheimer J, et al. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol 2009;30:227-33.
24. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005;17:359-65.
25. Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008;42:358-64.
26. Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38{alpha}-dependent pathway. J Leukoc Biol 2009;86:769-78.
27. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008;20:791-800.
28. Funakoshi-Tago M, Tago K, Hayakawa M, et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 2008;20:1679-86.
29. Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-{kappa}B and MAPKs. J Biol Chem 2004;279:13677-88.
30. Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551-5.
31. Ali S, Hubert M, Kollewe C, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007;104:18660-5.
32. Hayakawa H, Hayakawa M, Kume A, et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-80.
33. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277-81.
34. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930-5.
35. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptorinterleukin 1 receptor signaling. Nat Immunol 2003;4:920-7.
36. Bulek K, Swaidani S, Qin J, et al. The essential role of single Ig IL-1 receptor-related molecule/toll IL-1R8 in regulation of Th2 immune response. J Immunol 2009;182:2601-9.
37. Smithgall MD, Comeau MR, Yoon BRP, et al. IL-33 amplifies both T(h)1-and T(h)2-type responses through its activity on human basophils, allergen-reactive T(h)2 cells, iNKT and NK Cells. Int Immunol 2008;20:1019-30.
38. Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007;37:2779-86.
39. Rank MA, Kobayashi T, Kozaki H, et al. IL-33-activated dendritic cells induce an atypical T(H)2-type response. J Allergy Clin Immunol 2009;123:1047-54.
40. Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5(+) T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008;181:4780-90.
41. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526-34.
42. Suzukawa M, Likura M, Koketsu R, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008;181:5981-9.
43. Cherry WB, Yoon J, Barternes KR, et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90.
44. Suzukawa M, Koketsu R, Iikura M, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008;88:1245-53.
45. Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046-55.
46. Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc epsilon RI signals. J Leukoc Biol 2007;82:1481-90.
47. Moulin D, Donze O, Talabot-Ayer D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007;40:216-25.
48. Iikura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-8.
49. Allakhverdi Z, Smith DE, Comeau MR, et al. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051-4.
50. Allakhverdi Z, Comeau MR, Smith DE, et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009;123:472-8.
51. Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009;106:9773-8.
52. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46.
53. Humphreys NE, Xu D, Hepworth MR, et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008;180:2443-9.
54. Marvie P, Lisbonne M, L'helgoualc'h A, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med: Published Online First: 5 June 2009. doi:10.1111/j.1582-4934.2009.00801.
55. Matsuda A, Okayama Y, Terai N, et al. The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:4646-52.
56. Randolph DA, Stephens R, Carruthers CJ, et al. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999;104:1021-9.
57. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar Tlymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
58. Kobayashi T, Miura T, Haba T, et al. An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol 2000;164:3855-61.
59. Pesci A, Foresi A, Bertorelli G, et al. Histochemical characteristics and degranulation of mast cells in epithelium and lamina propria of bronchial biopsies from asthmatic and normal subjects. Am Rev Respir Dis 1993;147:684-9.
60. Ali M, Zhang G, Thomas WR, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 2009;73:206-12.
61. Oshikawa K, Yanagisawa K, Tominaga S, et al. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002;32:1520-6.
62. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2 mediated lung mucosal immune responses. J Exp Med 1999;190:895-902.
63. Liu X, Li M, Wu Y, et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009;386:181-5.
64. Kearley J, Buckland KF, Mathie SA, et al. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009;179:772- 81.
65. Sakashita M, Yoshimoto T, Hirota T, et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008;38:1875-81.
66. Chapuis J, Hot D, Hansmannel F, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry Published online 10 Feb 2009. doi: 10.1038/mp.2009.10.
67. Fraser A, Moore M, Jongbloed S, et al. Elevated soluble ST2 and cytokine levels in synovial fluids of patients with inflammatory synovitis [abstract]. Ann Rheum Dis 2006;65:A10.
68. Kuroiwa K, Arai T, Okazaki H, et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001;284:1104-8.
69. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998;187:787-94.
70. Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
71. Hitchon CA, Alex P, Erdile LB, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol 2004;31:2336-46.
72. Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002;297:1689-92.